GlaxoSmithKline PLC (GSK)

1,347.80
+17.60(+1.32%)
  • Volume:
    9,357,387
  • Bid/Ask:
    1,328.00/1,350.60
  • Day's Range:
    1,325.80 - 1,351.00

GSK Overview

Prev. Close
1,330.2
Day's Range
1,325.8 - 1,351
Revenue
32.43B
Open
1,326.8
52 wk Range
1,190.8 - 1,719
EPS
1.04
Volume
9,357,387
Market Cap
67.81B
Dividend (Yield)
80.00 (6.01%)
Average Vol. (3m)
8,392,828
P/E Ratio
12.90
Beta
0.68
1-Year Change
-21.04%
Shares Outstanding
5,031,444,276
Next Earnings Date
Jul 28, 2021
What is your sentiment on GlaxoSmithKline PLC?
or
Market is currently closed. Voting is open during market hours.

GlaxoSmithKline PLC News

GlaxoSmithKline PLC Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyStrong BuySell
Technical IndicatorsBuyStrong BuyStrong BuyBuyStrong Sell
SummaryBuyStrong BuyStrong BuyStrong BuyStrong Sell

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline PLC Company Profile

Employees
94066

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Read More
  • One thing i can tell you - if they remove Emma then thjs will fly - before thst happens this is dead - she has no idea of how to run a competitive business - dreadful performance - IPT
    0
    • Bullish consolidation. Next move coming.
      0
      • I'm waiting the next results (Next week). What do you think what will happen with the price? the company results will be good or not? Thanks!
        0
        • Haven't been bad in the past, reliable business. At least they have earnings compared to many stonks.
          0
      • When can we sell?
        0
        • 1650p
          0
        • Thanks
          0
      • Told you so. More buyers than sellers.
        0
        • So that's why it rises
          0
          • BRIEF-Hedge Fund Elliott Builds Up Multi-billion-pound Stake In UK's GSK - Ft
            0
            • TO THE MOON!
              1
              • It dropped quickly from 15 to 12. Now only 13.5. The rise for one day doesn't mean much
                0
              • PE is 11 still cheap.
                0
              • It dropped quickly from 15 to 12. Now only 13.5. The rise for one day doesn't mean much
                0
            • I bought at 12.15 on 4th March. Looking forward after all this time waiting!
              0
              • going to 20
                1
                • 20 what?
                  0
                • not going to 20 anytime soon unfortunately, years away
                  0
              • nice, going to moon now, too late for those who didnt buy under 13
                0
                • It's a bargain atm. Big solid company, great div and plays as a safe haven. Price is far below average consensus, so there is a room to raise.
                  0
                  • Don't count on the dividend because they will cut it soon
                    1
                  • Who says?
                    0
                • According to my data, there's still significant short interest on GSK. They might try to run stops on low volume to get the price down.
                  0
                  • I fear we wil fall till the 13s back soon
                    1
                  • Why sell? Don't like the great products or generous dividend? Don't get the trade idea for shorting / selling here....
                    1
                • Green at the of the day
                  1
                  • Target price £14.00
                    1
                    • great news about covid vaccine...GSK: -0.58%. LOL this stock is dead, I`m out today.
                      1
                      • I bought at £12.15 I hope this value improves soon!
                        1
                        • Downgraded to underperforming
                          2
                          • By the short sellers?
                            0
                          • Buy rating by Goldman Sachs
                            0
                        • with the news for medicago & gsk covid vaccine, i am seeing this back to 14
                          2
                          • value trap at moment; not a fan of Walmsley. However a) mainstream pharma suffering from covid due to all other medicines / ops delayed due to hospitals filled with covid b) other vaccines delayed due to to covid (& GSK are no 1 in world on vaccines) c) they didnt go into covid vaccine early on as they chose to licence their IP to others on how to make them stable for the elderly and at higher temperatures.  So this is likely to recover coming out of covid so its a 1/2 year hold sadly?
                            1
                            • I like your opinion. Any guess on the bottom or will it float around here
                              0
                            • JB Calls Hi, sorry... dont often look at GSk... I think it is close to the bottom and will consolidate here at least until end April when Q1 2021 data comes out. I cannot imagine this will be great and the year ago comparison will still be bad. Also the board are all selling shedloads at these prices which is concerning.  But the 9 day moving ave looks as if it will go through the 26 day moving ave to the upside shortly.  If i didn't have any i think i'd wait a bit longer for Q1 results; if you have some, be prepared to wait a year is my honest view.
                              1
                          • Someone wake up this stock. GSK is sleeping (and drowning)
                            1
                            • Very harsh article form seeking Alpha on GSK. Presented as a fact that  GSK will conduct value destroying acquisitions. Guidance evidently given by management.  I LIKE to be an contrarian and would BUY the stock below 13 GBP in size. See whos right, Seeking Alpha or Tomas.
                              1
                              • GSK is proving to be a train crash under Walmsley. Latest in the mediocre performance is that it's covid vaccine alliance with Sanofi doesn't work so won't have an offering in 2021. About time Walmsley was shown the door.
                                3
                                • Lol who are you? keep selling I Will keep buying. thank you
                                  1
                                • Like you I'm buying. GSK is a great company stuck in the slow lane due to management by committee. It's break up value is equivalent to at least £18/share (perhaps £20+ if you factor not paying a dividend). So I doubt Walmsley will get to separately list GSK as consumer and research, a more dynamic suitor will bid with much the same outlook. Shame really, a better management team should be able to pump up GSKs outlook without breakup. As I said, managerial train crash.
                                  1
                                • Mike Bamberyou have no idea how right you - managed by amateurs under the disguise of professionals is my take - and its an understatment
                                  1
                              • I find difficult that this will break resistance, there are not many better bets out there IMHO
                                1
                                • the decline is driven by the many unknowns surrounding the company split. if you check the earnings for 2020, they are actually not bad. the outlook for 2021 might be too conservative and it could surprise to the upside.
                                  1
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.